Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

CIBC Upgrades Mentor Corp.

CIBC World upgrades Mentor Corp. (MNT) to sector outperform from sector perform.

Analyst John Calcagnini bases his upgrade on an FDA panel recommendation to approve the company's silicone gel breast implant premarket approval with nine conditions by vote of 7 to 2.

He sets a $43 target, which is 50% probability weighted based on two potential scenarios: 1) FDA approving silicone premarket approvals of both Inamed, excluding Style 153 and Mentor, or 2) the FDA not approving either company's silicone implants.

Calcagnini says, should Mentor receive FDA approval and Inamed not get approval, Mentor stock should be valued somewhere north of $53 per share as the company gains market share.

blog comments powered by Disqus